KRAS and neoplasm: By using PDOs as a model system for evaluating clinically relevant drug responses, we conclude that KRAS and BRAF, but not MMR status, are dominant factors in determining the intrinsic sensitivity of tumor cells to chemotherapy and targeted therapy.